Chronic Nonbacterial Osteomyelitis in a Child with Previous Juvenile Dermatomyositis

To the Editor:

Chronic nonbacterial osteomyelitis (CNO) is a sterile osteitis of unknown etiology. The diagnosis is based on characteristic clinical, laboratory, and imaging features1. Currently, CNO is considered an autoinflammatory disorder. However, the association of CNO with inflammatory bowel diseases2, psoriasis3, and vasculitis suggests that both innate and adaptive immunity may contribute to pathogenesis.

A 3-year-old girl presented with proximal muscle weakness, Gottron papules, and periorbital heliotrope rash. Erythrocyte sedimentation rate (ESR) was 30 mm/h (normal 0–12 mm/h); creatine kinase, aspartate aminotransferase, and lactate dehydrogenase were normal. Antinuclear autoantibody (ANA) titers were 1:160; antibodies against Jo-1, ribonuclear proteins, Smith, Ro, La, Scl-70, and double-stranded DNA were not detected. Muscle biopsy result was consistent with dermatomyositis. She was started on oral corticosteroids 1.5 mg/kg/day and methotrexate 0.5 mg/kg weekly. After 9 months, muscle strength normalized and treatment was discontinued. Family history revealed that her brother and maternal grandmother had psoriasis and a paternal uncle was diagnosed with Crohn disease (Figure 1).

When she was 10 years old, she developed right distal femoral pain, swelling, and warmth and had elevated ESR (17 mm/h). Cultures from blood and from the affected bone were normal. A radiograph of the right femur revealed a mottled lucency (Figure 2A). Despite 2 months of intravenous antibiotics, the bone pain persisted. Magnetic resonance imaging (MRI) of the right leg showed a small sequestrum; bone biopsy was in keeping with nonbacterial osteomyelitis. The persistence of bone symptoms for another year, together with the results of a second bone biopsy, confirmed CNO. In addition, recurrent attacks of Raynaud phenomenon of the hands and feet commenced at 11 years of age, without additional features suggestive for connective tissue diseases. At age 17 years, she still had bone pain, swelling, and warmth. ESR was 20 mm/h and serum levels of muscle enzymes were normal. Femoral radiographs demonstrated unilateral small lucencies (Figure 2B); whole-body MRI confirmed the femoral lesion (Figure 2C). ANA titers were 1:160, extractable nuclear antibodies and anti-Scl-70 were negative. Whole exome sequencing did not reveal frameshift, stop gain or loss, or non-synonymous single-nucleotide polymorphisms for lipin 2 (LPIN2) or proline-serine-threonine phosphatase interacting protein 2 (PSTPIP2). She was restarted on naproxen 15 mg/kg/day, with good response.

Several lines of evidence show that CNO and the multifocal type, chronic recurrent multifocal osteomyelitis (CRMO), are autoinflammatory diseases4. High-titer autoantibodies or autoreactive antigen-specific T cells are not found in CNO. Even though CD20-positive B cells and CD8-positive T cells are present at the site of bone inflammation, neutrophils, and in particular, macrophages are the immune cells that play an important role in CNO5.

In contrast, juvenile dermatomyositis (JDM) is a “mixed” disorder, with both autoimmune and autoinflammatory features. These patients exhibit a vast repertoire of autoantibodies and a strong T cell response6. In addition, innate immunity also plays an important role in the pathogenesis of inflammatory myositis7. Complement activation induces secretion of proinflammatory cytokines and chemokines, facilitating the recruitment of macrophages, plasmacytoid dendritic cells (pDC), and T and B cells6. In JDM, there is a strong type I interferon signature, originated from pDC and from the myocytes where the unfolded protein response (UPR) is activated. Moreover, activation of UPR may trigger the innate immune pathways7.

What do these diseases have in common? Both CNO and JDM are systemic immune-mediated inflammatory diseases, characterized by cytokine dysregulation. Tumor necrosis factor-α, interleukin 10 (IL-10), and IL-18 play a role in pathogenesis of CRMO, whereas type I interferon has been implicated in JDM6,8,9. There is a strong innate response in the pathogenesis of both JDM and CNO. A link between these 2 diseases could be represented by IL-18, which can activate and amplify the intracellular T and B cell responses10.

We describe a unique case of CNO following JDM in a child with persistently positive ANA titers. From dysregulated adaptive immunity, characteristic for JDM, to prominent innate immune dysfunction, as is suspected in CNO, the child’s immune system responded in distinctive ways to as-yet unknown stimuli. Specific stimuli could have driven the signaling through either immune pathway at different times during childhood. We speculate that the treatment of JDM could have partially reset the immune system in this patient. On a subclinical tolerogenic background, a second hit could have stimulated the rapid-acting, non-specific innate immune system, leading to sterile bone inflammation. The sequential immune-mediated manifestations suggest there is crosstalk between the adaptive and innate immune arms, likely through common downstream signaling pathways and/or transcriptional targets. Autoinflammatory and autoimmune disorders are diseases of immune dysregulation, manifesting along a broad phenotypic spectrum.

DANIELA S. ARDELEAN, MD, FRCP. Research Fellow, Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, and Department of Immunology, University of Toronto, Toronto, Ontario; PETER B. DENT, MD, DCH, FRCP. Professor Emeritus, Division of Rheumatology and Immunology, McMaster University, Hamilton, Ontario; POLLY J. FERGUSON, MD, FAAP, Associate Professor, Division of Pediatric Hematology, Oncology and Rheumatology, University of Iowa Children’s Hospital, Iowa City, Iowa, USA; RONALD M. LAXER, MD, Professor, Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Dr. Ardelean is supported by a Fellowship from CIHR/CAG/Abbott; and PGME/Department of Pediatrics, Department of Immunology, MOH/CIP, University of Toronto.

Address correspondence to Dr. R.M. Laxer, Division of Rheumatology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. E-mail: ronald.laxer@sickkids.ca
REFERENCES


J Rheumatol 2013;40:3; doi:10.3899/jrheum.120963